EAGLE PHARMACEUTICALS INC (EGRX) Stock Price, Forecast & Analysis
NASDAQ:EGRX • US2697961082
EGRX Key Statistics, Chart & Performance
The current stock price of EGRX is 2.14 USD. In the past month the price decreased by -53.58%. In the past year, price decreased by -84.56%.
EGRX Technical Analysis
EGRX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to EGRX. EGRX has an excellent profitability rating, but there are concerns on its financial health.
EGRX Financial Highlights
Over the last trailing twelve months EGRX reported a non-GAAP Earnings per Share(EPS) of 4.66. The EPS decreased by -33.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 4.7% | ||
| ROA | 2.99% | ||
| ROE | 4.8% | ||
| Debt/Equity | 0.25 |
EGRX Forecast & Estimates
7 analysts have analysed EGRX and the average price target is 17.34 USD. This implies a price increase of 710.28% is expected in the next year compared to the current price of 2.14.
For the next year, analysts expect an EPS growth of -40.26% and a revenue growth -19.31% for EGRX
EGRX Ownership
EGRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.73 | 405.578B | ||
| AMGN | AMGEN INC | 16.89 | 204.31B | ||
| GILD | GILEAD SCIENCES INC | 16.59 | 185.891B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.92 | 122.042B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.65 | 83.206B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.38 | 43.51B | ||
| INSM | INSMED INC | N/A | 33.916B | ||
| NTRA | NATERA INC | N/A | 29.129B | ||
| BIIB | BIOGEN INC | 12.86 | 28.815B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.05 | 20.433B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EGRX
Company Profile
Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 134 full-time employees. The company went IPO on 2014-02-12. The firm is focused on developing medicines that result in improvements in patients' lives. The firm's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The firm also has a research and development facility in Cambridge, Massachusetts. The firm has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana. The Company’s subsidiaries include Eagle Biologics, Inc., Eagle Research Lab Limited, Acacia Pharma Group plc, Acacia Pharma Limited and Acacia Pharma Inc.
Company Info
EAGLE PHARMACEUTICALS INC
50 Tice Boulevard, Suite 315
Woodcliff Lake NEW JERSEY 07677 US
CEO: Scott Tarriff
Employees: 134
Phone: 12013265300
EAGLE PHARMACEUTICALS INC / EGRX FAQ
What does EGRX do?
Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 134 full-time employees. The company went IPO on 2014-02-12. The firm is focused on developing medicines that result in improvements in patients' lives. The firm's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The firm also has a research and development facility in Cambridge, Massachusetts. The firm has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana. The Company’s subsidiaries include Eagle Biologics, Inc., Eagle Research Lab Limited, Acacia Pharma Group plc, Acacia Pharma Limited and Acacia Pharma Inc.
What is the stock price of EAGLE PHARMACEUTICALS INC today?
The current stock price of EGRX is 2.14 USD. The price decreased by -39.89% in the last trading session.
Does EGRX stock pay dividends?
EGRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of EGRX stock?
EGRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What do analysts say about EAGLE PHARMACEUTICALS INC (EGRX) stock?
7 analysts have analysed EGRX and the average price target is 17.34 USD. This implies a price increase of 710.28% is expected in the next year compared to the current price of 2.14.
What is the GICS sector and industry of EGRX stock?
EAGLE PHARMACEUTICALS INC (EGRX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the growth outlook for EAGLE PHARMACEUTICALS INC?
The Revenue of EAGLE PHARMACEUTICALS INC (EGRX) is expected to decline by -19.31% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.